Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID‑19 during the periods of alpha, delta and omicron variant predominance

Mathioudakis, Nikolaos; Zachiotis, Marinos; Papadakos, Stavros P.; Triantafyllou, Maria; Karapanou, Αmalia; Samara, Stamatia; Karamanakos, Georgios; Spandidos, Demetrios A.; Papalexis, Petros; Damaskos, Christos; Tarantinos, Kyriakos; Fotakopoulos, George; Sklapani, Pagona; Τράκας, Νικόλαος; Sipsas, Nikolaos V.; Georgakopoulou, Vasiliki

doi:10.3892/etm.2022.11611

Cited by 6 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…--------------------------------------------------------- -------------------------------------------------------- respiratory syndrome, with a COVID-19 mortality rate of up to 60% (27,28). Biomarkers such as NLR, CAR and albumin have all been reported as predictors of poor outcomes in patients with COVID-19 (29)(30)(31). To the best of our knowledge, the present study is the first to demonstrate the association of these specific inflammatory biomarkers with unfavourable outcomes among elderly patients receiving early remdesivir treatment, indicating the critical role of the nutritional and inflammatory state of these patients in the course of the disease.…”

Section: Discussionmentioning

confidence: 99%

Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Remdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective in hospitalized patients, its use gained approval in early-stage disease for symptomatic outpatients who are at a high risk of progression to severe disease. The present study is a real-life prospective cohort study involving 143 elderly non-hospitalized patients with SARS-CoV-2 (≥65 years of age) who attended the emergency department of the authors' hospital seeking care for COVID-19 symptoms appearing within the prior 7 days. Eligible patients received intravenous remdesivir at a dose of 200 mg on the first day and 100 mg on days 2 and 3. The efficacy endpoints were set as the need for COVID-19-related hospitalization and all-cause mortality in the following 28 days. A total of 143 patients participated in the study. Of these patients, 118 (82.5%) patients were vaccinated with at least two doses. All patients enrolled completed the 3-day course, with a total of 6 out of 143 patients (4.2%) having a COVID-19-related hospitalization by day 28, and 5 patients (3.5%) succumbing to the disease within the study period. In the univariate Cox regression analysis, the neutrophil-to-lymphocyte ratio and haematological malignancy were identified as predictors of progression to severe disease, and albumin levels, the C-reactive protein-to-albumin ratio (CAR) and haematological malignancy were identified as predictors of 28-day mortality. On the whole, the findings of the present study demonstrated that among the elderly outpatients, a 3-day course of intravenous remdesivir was associated with favourable outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…In recent years, the field of medical research has been confronted with immense challenges and has achieved significant advancements with regards to coronavirus disease 2019 (COVID-19) and obesity, both of which are conditions that are forming global health crises with varying degrees of coverage, attitudes and actions (1)(2)(3)(4). The interconnectedness of COVID-19 and obesity is addressed in the present article, which also highlights the complex nature of the interaction between these two prevalent problems in global health (1,2,(5)(6)(7)(8)(9)(10).…”

Section: The Interconnectedness Of Covid-19 and Obesitymentioning

confidence: 89%

The parallel lives of pandemics: COVID‑19 and obesity

Georgakopoulou,

Lempesis,

Spandidos

2024

Exp Ther Med

Self Cite

View full text Add to dashboard Cite

The present article discusses the interconnectedness of coronavirus disease 2019 (COVID-19) and obesity as global health crises. The similarities between the two conditions are highlighted; these include shared risk factors and comorbidities, and the impact of obesity on the immune system. The present article also mentions the challenges faced in combating both pandemics, including misinformation and prejudice against obesity. It discusses the development of therapeutic medications and vaccines for COVID-19 and the potential of injectable incretin analogues for weight loss. Socioeconomic issues are also addressed, with obesity being more prevalent in lower socioeconomic groups and the cost of obesity treatments being a barrier for those in need. The present article emphasizes the need for comprehensive and sustainable solutions, including public health interventions, education, policy changes and equitable distribution of resources, to address both COVID-19 and obesity.

show abstract

“…Serum albumin levels have been linked to poor outcomes in patients with COVID-19. As a typical nutritional indicator, low albumin levels in patients with COVID-19 may be a marker of excessive consumption due to tissue damage and hypermetabolism ( 21 ). A recent study demonstrated that higher serum albumin levels are significantly associated with improved cognitive function and play a protective role in motor impairment and PD-related mortality ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

Characteristics and outcomes of elderly patients with Parkinson's disease hospitalized due to COVID‑19‑associated pneumonia

Georgakopoulou

Gkoufa

Bougea

et al. 2023

Med Int

Self Cite

View full text Add to dashboard Cite

Patients with Parkinson's disease (PD) and coronavirus disease 2019 (COVID-19)-associated pneumonia present, according to the literature, high mortality rates due to the nature of the disease, advanced age, and underlying diseases. Most available studies, however, refer to the first waves of the pandemic. The aim of the present study was to investigate the clinical characteristics and outcomes of elderly patients (≥65 years old) with PD hospitalized with COVID-19-associated pneumonia during the period of prevalence of various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, as well as to determine possible prognostic factors for poor outcomes. During the period from February 15, 2021, to July 15, 2022, 1,144 elderly patients with COVID-19 pneumonia were hospitalized. Age, sex, Charlson comorbidity index, vaccination status against SARS-CoV-2, and admission laboratory parameters were recorded for all patients. A total of 36 (3.1%) patients with PD were hospitalized due to COVID-19-associated pneumonia (18 males, 50%). The mean age of the patients was 82.72±8.18 years. In total, 8 patients (22.2%) were hospitalized during the period of alpha variant predominance, 3 patients (8.3%) during the period of delta variant predominance, and 25 patients (69.4%) during the omicron variant predominance period. Of note, 16 patients (44.4%) were vaccinated with at least two doses. In addition, 17 (47.2%) patients succumbed to the disease. Between the patients who survived and those who succumbed, a statistically significant difference was only found in the mean value of albumin (37.48±6.02 vs. 31.97±5.34 g/l, P=0.019). In particular, as shown by receiver operating characteristic curve analysis, albumin exhibited a satisfactory predictive ability for mortality (area under the curve, 0.780; P=0.013) with an albumin value ≤37.7 g/l being able to predict mortality with 85.7% sensitivity and 54.8% specificity. Overall, the findings of the present study indicate that mortality among elderly patients with PD hospitalized with COVID-19-associated pneumonia was high in all phases of the pandemic. A low albumin value, not only as an indicator of the immune status, but also of the nutritional status, is a predictor of adverse outcomes.

show abstract

Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID‑19 during the periods of alpha, delta and omicron variant predominance

Cited by 6 publications

References 38 publications

Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study

Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study

The parallel lives of pandemics: COVID‑19 and obesity

Characteristics and outcomes of elderly patients with Parkinson's disease hospitalized due to COVID‑19‑associated pneumonia

Contact Info

Product

Resources

About